Tag-free, specific conjugation of glycosylated IgG1 antibodies using microbial transglutaminase

• Published in: RSC advances 2022-11, Vol.12 (52), p.3351-33515
• Main Authors: Hadjabdelhafid-Parisien, Adem, Bitsch, Sebastian, Macarrón Palacios, Arturo, Deweid, Lukas, Kolmar, Harald, Pelletier, Joelle N
• Format: Article
• Language: English
• Subjects: Antibodies; Chemical synthesis; Chemistry; Conjugation; Glutamine; Mass spectrometry; Microorganisms; Payloads; Toxicity
• ISSN: 2046-2069; 2046-2069
• DOI: 10.1039/d2ra05630e

We present an efficient approach for tag-free, site-specific conjugation of a fully glycosylated antibody using microbial transglutaminase (mTG). We created variants of trastuzumab where a single surface-exposed residue of the human crystallizable fragment had been substituted to glutamine, with the objective of enabling site-specific mTG-mediated conjugation with primary amine payloads. MTG reactivity was determined by conjugation to an amino fluorophore, demonstrating effective tag-free conjugation at the newly introduced I253Q site. The conjugation of one payload per antibody heavy chain was confirmed by mass spectrometry. We further demonstrated two-step mTG/click chemistry-based conjugation of I253Q trastuzumab with monomethyl auristatin E. Cytotoxicity and specificity of the resulting antibody-drug conjugate were indistinguishable from trastuzumab conjugated by another method although binding to the neonatal Fc receptor was impaired. The resulting fully glycosylated ADC is unique in that it results from minimal modification of the antibody sequence and offers potential for application to cellular imaging, fluorescence microscopy, western blotting or ELISA. Substitution I253Q on a glycosylated IgG1 antibody allows microbial transglutaminase-mediated conjugation of a fluorophore or a clickable auristatin. The resulting antibody-drug conjugate showed excellent cell toxicity and no FcRn-mediated recycling.